Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →A data-backed look at sequence read alignment algorithm patents for genome mapping: 509 records, filing trends through 2026, IPC composition, leading assignees
Filing growth = 2018 (22 records) → 2021 (43); 2021 is the last year we treat as complete. MIRECULE INC is named on 16 of the 509 published records in scope. One published record can name several filers, so these figures are not slices of a divided whole and do not add up.
Sequence read alignment sits at the intersection of computer science and molecular biology, and the patent record reflects that split. 509 records filed between 2015 and the 2026 cut-off show no single company controlling the field: the leading assignee holds only 16 records, and the top five combined reach just 13.9% of all 509 records in scope. Filing activity rose steadily for over a decade, peaked in 2022, and has since pulled back, though the most recent years are still filling in because publication lags filing by roughly 18 months.
Nearly half of all records carry a G16B bioinformatics classification, but a large minority also touch enzyme and DNA measurement methods (C12Q) or electric data processing (G06F), showing that alignment algorithms rarely stand alone as pure software claims, most are tied to a sequencing platform, a diagnostic workflow, or a specific data-processing architecture.
Counted over all 509 published records, including filings from before 2007; the filing-trend chart below covers only the 441 records from 2007 onward, so the two charts are not the same set of documents. Ordered by volume only, not by importance or claim strength. Counted in published records, so one invention filed in several countries counts more than once. Names come from Patsnap's standardised assignee field as recorded on each document; subsidiaries and group companies are not merged. The icon before each name is read from the name itself (words such as University, Institute or Ltd); the data carries no organisation-type field, so treat it as a reading aid rather than a classification. Filings held by named individuals rather than organisations are removed where they can be identified (9 here); that identification is not exhaustive, so an individually held filing can still appear below. Either way those filings stay inside the totals above. This table shows the top 30 of the 91 filers returned for this search; the data endpoint returns at most 100 entities, so even that 91 is not the complete set of filers. A single record can name more than one filer, so these counts overlap and do not add up to the total.
Pick a task. Every answer cites the patents behind it.
The 509 records in scope span 2015 through the 2026 cut-off, with publication activity concentrated in bioinformatics and enzyme/DNA measurement classes and filings spread across six major receiving offices.
Annual filings climbed from 8 in 2007 to a peak of 64 in 2022, then declined to 21 by 2024, a complete year, for a -51% change over 2021-2024. 2025 and 2026 figures are still incomplete because publication lags filing by roughly 18 months, so the most recent years understate actual filing activity and should not be read as a slowdown on their own.
Counted in published records by earliest filing year, not de-duplicated into families. A filing is counted in the year it was filed, but it only becomes visible after it publishes: roughly 18 months for most routes, and up to 30 months where a PCT application enters national phase. 2022 onwards are therefore still filling in and are shaded; no growth figure on this page uses them. Because this series counts documents rather than inventions, a rise can mean more inventions or the same inventions filed in more countries; this dataset cannot separate the two. The growth figure above therefore stops at 2021. This chart covers 2007-2026 (441 records); the 509 total quoted above includes earlier filings outside the window.
G16B bioinformatics claims appear in 49.7% of the 509 records, ahead of C12Q enzyme/DNA measurement methods at 28.1% and G06F electric data processing at 26.3%. Because a single record can carry several IPC classes, these shares add to more than 100% of the record total, the chart reflects that overlap rather than a partition of the field.
Shares are the percentage of the 509 published records in scope. One published record can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about sequence read alignment algorithm for genome mapping patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaA method is presented for aligning a read with a reference substring of a genome sequence. The method includes: receiving a banded portion of a matrix from a sequence alignment algorithm; calculating a score threshold for the banded portion of the matrix, where value of the score threshold is calculated as a function of a scoring method used by the sequence alignment algorithm; identifying a high score amongst the cells in the banded portion of the matrix; and comparing the high score to the score threshold. Performing variant calling using the banded portion of the matrix when the high score is greater than to the score threshold.Filed by The Regents of the University of Michigan, published 2020-07-23 as US20200234796A1.


Selected as the first record the search returns under the database default order, then shown in full. It is not ranked by citations, claim breadth or commercial importance, and it is not a judgement about which filing in this space matters most.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Four figures from this dataset matter more than the rest for deciding where to file, litigate, or license.
The leading assignee holds 16 records out of 509, and the top five combined reach only 13.9% of the field. Freedom-to-operate risk is distributed across many independent filers rather than concentrated in one blocking portfolio.
Annual filings hit 64 in 2022, then fell to 21 by 2024, a complete year, for a -51% change over that span. Publication lag of roughly 18 months means 2025-2026 numbers will keep rising as more filings publish.
G16B bioinformatics claims appear in half the corpus, nearly double the next class, C12Q enzyme/DNA measurement methods at 28.1%. Records often carry both, reflecting alignment algorithms embedded in wet-lab measurement pipelines.
The United States receives 114 filings, ahead of the WIPO PCT route at 88 and the EPO at 78, with China, India and Canada following. This mirrors where sequencing and diagnostics commercialisation is concentrated.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to sequence read alignment algorithm for genome mapping patent landscape, with the prior art for and against each one.
The figures above set the boundaries of the field. These are the follow-up questions worth running before committing to a filing or freedom-to-operate strategy.
US20200234796A1's banded-matrix threshold mechanism is narrow but specific, confirm whether a planned alignment architecture uses banding and scoring-derived thresholds before treating the space as open.
Run a claim comparison in Eureka →2024 is the last complete filing year at 21 records, down from a 2022 peak of 64; 2025-2026 figures will rise as publication lag resolves, so re-check this trend in a future data pull before concluding the field has cooled.
Monitor filing trends in Eureka →Healthcare informatics integration and protein-specific alignment methods remain thin relative to the bioinformatics core, suggesting room for claims that bridge alignment output into clinical workflows or protein-coding-specific scoring.
Explore white space in Eureka →Filing is spread across a broad set of organisations rather than concentrated in one company. This pattern is typical of a field still being worked out by universities, sequencing platform vendors and government research bodies simultaneously.
Filings rose steadily from 8 in 2007 to a peak of 64 in 2022, then fell to 21 by 2024, a complete filing year, for a -51% change over that three-year span. Figures for 2025 and beyond are not yet reliable because patent publication typically lags the actual filing date by around 18 months, so those years will keep filling in. Treat the post-2022 numbers as provisional rather than evidence of a genuine slowdown.
The most common class is G16B, bioinformatics, appearing in 49.7% of the 509 records, followed by C12Q, methods involving enzymes and DNA measurement, at 28.1%, and G06F, electric digital data processing, at 26.3%. Medicinal preparations (A61K), peptide and protein chemistry (C07K), and material analysis (G01N) each appear in a minority of records. Because records often carry multiple IPC codes, these percentages overlap rather than sum to 100%, reflecting how alignment algorithms sit at the intersection of software, molecular biology and diagnostics.
The United States leads as a receiving office with 114 filings, followed by the WIPO PCT route at 88 and the European Patent Office at 78. China follows with 49, then India with 30 and Canada with 27. This spread indicates that applicants are pursuing multi-jurisdiction protection through PCT alongside direct national filings, consistent with a technology used in globally distributed sequencing and diagnostics markets.
US20200234796A1, assigned to The Regents of the University of Michigan, claims a method for evaluating a banded portion of a sequence alignment matrix by computing a score threshold derived from the alignment's scoring method, then gating variant calling on whether the region's high score exceeds that threshold. It does not cover sequence alignment or variant calling broadly; it covers this specific banded-matrix, scoring-derived threshold mechanism. Alignment approaches that use full (non-banded) matrices, or that apply fixed rather than scoring-derived thresholds, sit outside its literal claim scope, though a freedom-to-operate review is advisable before building on banded dynamic-programming designs.
Go past this page: query the whole sequence read alignment algorithm for genome mapping patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Search. Every figure on this page comes from one Patsnap search, run once and not edited afterwards. This is the exact search string:
TAC:(("read alignment" OR "sequence alignment") AND (genome OR reference) AND algorithm)
Reading the field codes: TAC searches the title, abstract and claims of each record, not the full description. The search string sets no date limit, so the scope is every matching record in the database regardless of when it was filed. It is not restricted to recent years. How this string was built matters for how far the counts can be pushed. It was generated in batch from a topic list rather than hand-crafted for this page, and the result set is not manually screened. A keyword search over title, abstract and claims both over-captures (unrelated filings that happen to use the same words) and under-captures (the same invention written in different words). This page cannot measure either effect, so read every figure here as what this particular string returned, not as what exists in the field. No subclass carries much of this set: the most common one is on 49.7% of the published records and the set spans 51 subclasses in all. That can mean the technology genuinely sits across several areas, or that the search string is also matching adjacent work that happens to use the same words. This page cannot separate the two, and the result set is not screened by hand.
What is being counted. Two different units appear on this page and they are not interchangeable. The filer list and the technology split are counted in simple (DOCDB) patent families: one invention counts once however many countries it was filed in. The total, the jurisdiction split and the filing-year chart are counted in published records: the same invention counts once per publication. Record counts reward filing in many jurisdictions; family counts do not. Shares are only ever taken against a denominator in the same unit, and each one names it.
Who the filers are. Names come from Patsnap's standardised assignee field, as recorded on the documents themselves. They are not rolled up to corporate group: a parent and its subsidiaries appear as separate entries, and a portfolio acquired from another company stays under the name on the document unless the assignment is reflected there. This list is meant to carry organisations, not people. Filings held by a named individual are identified by matching the assignee against the inventors on the same search, and, for names written in Chinese, Japanese or Korean characters, by the name carrying no organisational suffix; those are removed from the list (9 of them here). Neither test is exhaustive: the inventor list it matches against is itself capped, and a personal name written in Latin script with no organisational wording in it cannot be told apart from a short company name by rule. So an individually held filing can still appear in the list. Those filings stay inside every total and share on this page either way, so the listed entries can add up to less than the total. A record shown in full further down still names its assignee exactly as the patent office records it, including where that is a person: that name is how the record is identified and checked. What is left out of the ranking is people as ranked entries, not people as cited sources. The table shows the top 30 of the 91 filers returned, ordered by count alone; the data endpoint returns at most 100 entities, so even that 91 is not every filer. One published record can name several filers and each is counted separately, so these rows are not slices of a divided whole: adding them together over-counts, and this page deliberately publishes no combined "top five" share for that reason. See every filer, individuals included
Dates. The year chart counts by earliest filing year, not publication year. A filing only becomes visible once it publishes: roughly 18 months for most routes, and up to 30 months where a PCT application enters national phase. Measured across these pages, the year four back from today still holds only about 89% of its eventual count. 2022 onwards are therefore shaded on the chart as still filling in, and the growth figure stops at 2021. The data behind this page was retrieved shortly before the publication date shown above.
Legal status. Legal status was not available for this search, so no in-force figure is shown. Get the status breakdown in Eureka
Classification. The technology split uses IPC subclasses (four characters, for example H01M). A single record usually carries several, so the shares add up to more than 100% and a record can appear in more than one bar. Subclass is a coarse grouping; it describes the field a record was classified into, not what the claims cover. Break the classes down to subgroup level
Who wrote the words. The tables, charts, counts, shares and patent numbers on this page are produced directly from the search result by a program; none of them are written or estimated by a language model. The surrounding prose, headings, FAQ answers and the answers in the question panel are drafted by a language model that is given those same figures and is not permitted to introduce others. Prose can still mis-describe a correct figure, so where the two disagree, the tables and charts are the record.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries limitations that apply to every figure above. Recent filings are under-counted, because an application is not public until roughly 18 months after filing and database loading adds further delay. The search string defines and constrains everything shown: records that use different terminology, or that sit outside the fields searched, are absent and cannot be counted. Applicant names, classification codes, legal-status codes and citation records are taken as recorded and may contain errors, duplicates, omissions or stale entries. Ordering by volume is not a measure of quality, scope, enforceability or commercial value, and a larger portfolio is not a stronger one. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, validity or infringement search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. No attorney-client relationship is created by it. Any patent, commercial, or strategic decision should be verified independently against the primary records and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
The question panel. The answers behind the suggested questions on this page were written when the page was generated, not in response to your click. The progress steps that play before an answer appears are an animation of how that analysis was done; nothing is being searched or computed at that moment. Typing your own question instead opens Patsnap Eureka, which does run it live.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page